Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies

Summary

Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject with Locally Advanced or Metastatic Solid Malignancies Phase I. Advanced or metastatic solid malignancy First in Human. HSP90 inhibitor Multi-center clinical trials. Open label. To determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640

Timeline

Start

2025-12

Primary completion

2027-11

Completion

2027-11

Outcome

Outcome not reported

Stopped: “Study held.”

Drugs

Indications